junshi out-licens ex-gratia china right lilli
substanti mileston fee first domest
antibodi drug out-licens mnc believ
testimoni boost junshi lead posit field
commerci opportun could also substanti
depend durat scale outbreak
second wave outbreak similar scale first
wave occur estim sale contribut junshi could
reach bn exclud mileston fee
tuoyi label expans npc uc horizon tuoyi becam
first drug whose nda npc accept china
addit tuoyi npc trial complet enrol
expect nda also expect tuoyi nda uc
accept near futur second type china
remain outperform lift tp
increas revenu forecast factor
potenti sale better commerci visibl tuoyi
npc uc
number share mn
chg prev ep
estimate pot chg tp
figur revenu market potenti
may junshi announc collabor
develop commercialis antibodi drug
base agreement junshi would out-licens
develop commerci right lilli region
outsid greater china mainland china hong kong macau
taiwan exchang lilli pay junshi up-front fee
mn mileston payment mn
antibodi two antibodi candid double-digit royalti
net sale addit lilli negoti junshi subscrib
mn new share compani first domest
antibodi drug out-licens mnc believ
testimoni boost junshi lead posit field
china global
accord institut microbiolog chines academi scienc
imca develop well track encourag anim
efficaci data treatment protect safeti profil
expect submit ind near futur think
current lilli collabor boost confid
commerci opportun could also substanti
depend durat scale
outbreak
current still patient china
row rest world accord expert second wave
scale less first wave like
occur winter could anoth new case
china row second wave hand think
limit competitor hand compani
made solid progress antibodi regeneron
depend suitabl patient criteria drug price sale
contribut junshi could reach sever hundr million even
bn exclud mileston fee estim
tuoyi label expans npc uc horizon
april tuoyi becam first drug whose nda new
drug applic line npc nasopharyng carcinoma
accept china base phase data use orr primari
endpoint data regard nda reveal previous
junshi report interim phase result tuoyi npc
orr patient main competitor npc
hengrui akesobio whose nda expect addit
tuoyi npc trial complet enrol expect nda
also expect tuoyi nda uc urotheli carcinoma
accept near futur although timelin later
competitor drug tisel beigen think tuoyi could grab larger
market share due broader patient base
superior efficaci data higher orr longer os
remain outperform lift tp
increas revenu factor potenti
sale better commerci visibl tuoyi
npc
uc think junshi stock upsid potenti driven multipl
near-term key catalyst includ approv launch tuoyi
uc npc stib list continu progress drug
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau univers toronto compani mention price
fei zheng jason liu certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part compens
directli indirectli relat specif recommend view express report
price rate histori beigen bgne oq
signifi initi assumpt coverag
price rate histori beigen
signifi initi assumpt coverag
charl martineau univers toronto price rate histori inc regn oq
signifi initi assumpt coverag
price rate histori shanghai junshi bioscienc co ltd
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european exclud turkey rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less
attract underperform least attract invest opportun latin america turkey asia exclud japan australia
stock rate base stock total return rel averag total return relev countri region benchmark india
bse sensex index prior octob canadian rate base stock absolut total return potenti
current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk
prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
charl martineau univers toronto market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
